ArticleEndocrine2026
Combination of hsa-miR-21-3p/ sTNF-RI/ IL12-p40 /CCL25 serves as a promising panel of diagnostic biomarkers for distinguishing malignant from benign nodules in papillary thyroid cancer.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePapillary thyroid cancer (PTC) is the most common thyroid malignancy and is often difficult to distinguish from benign nodules using current diagnostic tools, resulting in unnecessary surgical interventions. This study aimed to identify robust, reliable, and non-invasive circulating biomarkers capable of accurately discriminating benign from malignant PTC nodules by elucidating the relationship between thyroid tissue and circulating microRNA/cytokine profiles.
methodsPaired arterial plasma supplying the thyroid gland and venous plasma draining the gland were collected from patients with benign thyroid nodules and malignant PTC. In addition, preoperative and postoperative peripheral plasma samples were obtained. MicroRNA profiles were compared between arterial inflow and venous outflow to assess thyroid-derived contributions to circulating biomarkers. Differentially expressed microRNAs were validated in preoperative and postoperative peripheral plasma samples and formalin-fixed, paraffin-embedded (FFPE) thyroid tissue sections. Subsequently, cytokine profiles associated with target microRNAs were investigated using cytokine arrays, and selected target proteins were further validated by ELISA.
resultsArterial–venous comparisons revealed distinct microRNA and cytokine signatures associated with malignant PTC compared with benign nodules, reflecting tumor-specific release into the circulation. These findings were consistently validated in FFPE tissues and peripheral plasma samples. Importantly, the combined panel of hsa-miR-21-3p, sTNF-RI, IL-12p40, and CCL25 demonstrated high diagnostic performance in distinguishing malignant PTC from benign thyroid lesions. DISCUSSION: This integrated tissue-to-circulation approach provides direct evidence that the thyroid microenvironment significantly contributes to the circulating biomarker landscape. The identified biomarker panel represents a promising non-invasive diagnostic tool with the potential to improve PTC diagnosis, reduce unnecessary surgical procedures, and support clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.